RxDoctor Payments Data

Martha Young, NP

Psychiatric/Mental Health · Ann Arbor, MINPI 1255485629

Payments from drug & device makers

$829in general payments, 2019–2025

Across 35 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$252
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
  • Neurocrine Biosciences, Inc.$84
  • Otsuka America Pharmaceutical, Inc.$67
  • Teva Pharmaceuticals USA, Inc.$56
  • Alkermes, Inc.$42
  • plus $103 from 4 others

What the payments were for

  • Food & beverage$78294%
  • Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$829 in reported general payments places this provider in the 55th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$3,055
Medicare patients
20
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole18$44,504
CaplytaLumateperone Tosylate13$20,402
Aripiprazole34$7,306
Paliperidone ErPaliperidone12$5,985
Lithium Carbonate ErLithium Carbonate27$446
Quetiapine Fumarate30$348
Duloxetine Hcl14$177
Lithium Carbonate15$150
Clonazepam26$136
Lamotrigine14$119
Sertraline Hcl13$105
Trazodone Hcl14$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$67$44,50418 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$224$20,40213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →